



Auxilium Pharmaceuticals, Inc.




AUXL NASDAQ

Pharmaceuticals - Diversified

Market Capitalization USD:

\$718.76 mm

CONCERN LEVEL: AVERAGE

- 1 The CEO's total remuneration is within the typical market range for the relevant industry and market cap.
- 2 The ratio between the CEO's pay and the median pay of the other named executive officers is 3X or less.
- 3 The CEO's annual cash incentives rose or fell in line with annual performance.
- 4 The CEO received no more than one annual cash bonus this fiscal year.
- 5 The CEO's equity remuneration reflected the company's share price movement over the last five years.
- 6 The company only pays long-term incentives to the CEO for above median performance against a peer group. 
- 7 The company's dilution from equity incentives is 10 percent or less. 
- 8 Unvested equity lapses when the CEO's employment is terminated. 
- 9 The CEO's potential cash severance payment is capped at two times annual cash remuneration.
- 10 The accrued benefits of the CEO's post-retirement income are within the typical market range for the relevant market cap bracket.

CEO: Adrian Adams

Age: 62

CEO Since: 2011

	2009	2010	2011
Base Salary	\$524,538	\$549,808	\$598,660
Discretionary Bonus	\$0	\$0	\$0
Annual Cash Incentive	\$550,000	\$202,400	\$0
Benefits and Perquisites	\$7,258	\$12,834	\$5,672
TOTAL ANNUAL COMPENSATION	\$1,081,796	\$765,042	\$604,332
Increase in Post-Retirement Benefits	\$0	\$0	\$0
Stock Option Awards	\$1,080,030	\$2,320,680	\$1,132,490
Stock Awards	\$693,000	\$181,200	\$368,068
TOTAL COMPENSATION	\$2,854,826	\$3,266,922	\$2,104,890
Median of Other Named Executive Officers Total Compensation	\$1,251,346	\$985,952	\$1,977,991
Value Realized on Exercise of Stock Option	\$1,332,276	\$757,815	\$422,392
Value Realized on Vesting of Stock	\$1,380,000	\$2,020,287	\$320,395
TOTAL REALIZED EQUITY COMPENSATION	\$2,712,276	\$2,778,102	\$742,787

Proxy Date: 27 Apr 2012

Annual Meeting Date: 21 Jun 2012

Equity Reserves: 26.22%

Stock Option Run Rate: 3.85%

Auxilium Pharmaceuticals, Inc.


AUXL NASDAQ

Pharmaceuticals - Diversified

Market Capitalization USD: **\$718.76 mm**

Performance Comparison

■ S&P500 ■ Industry ■ AUXL



Peer Comparisons (TRBC) =Pharmaceuticals - Diversified

Total Summary CEO Compensation

Ticker	Company Name	2009	2010	2011	Market Cap
AUXL	Auxilium Pharmaceuticals, Inc.	\$2,854,826	\$3,266,922	\$2,104,890	\$718,760,936
THRX	Theravance, Inc.	\$2,300,609	\$1,946,398	\$6,840,942	\$1,707,207,118
AMLN	Amylin Pharmaceuticals, Inc.	\$3,710,755	\$4,756,844	\$4,409,332	\$1,346,595,842
ARIA	ARIAD Pharmaceuticals, Inc.	\$1,201,590	\$2,131,093	\$3,859,658	\$1,165,089,677
PRX	Par Pharmaceutical Companies, Inc.	\$3,667,258	\$3,647,097	\$4,373,950	\$971,700,117
AKRX	Akorn, Inc.	\$2,073,241	\$4,021,109	\$4,462,720	\$738,205,977
OPTR	Optimer Pharmaceuticals, Inc.	\$1,068,180	\$4,976,699	\$1,654,935	\$644,989,685

To insure consistency, peer comparisons are based on a combination of TRBC Industry and Sector classifications and company market caps. Missing peer pay figures for 2011 are due to differences in company filing schedules.

Pay Peer Group

Acorda Therapeutics Inc., InterMune, Inc., Alkermes, Inc., Isis Pharmaceuticals, Inc., Amylin Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., BioMarin Pharmaceutical, Inc., Medicis Pharmaceutical Corporation, Cubist Pharmaceuticals, Inc., Onyx Pharmaceuticals Inc., Dendreon Corporation, Salix Pharmaceuticals, Ltd., Emergent BioSolutions, Inc., Seattle Genetics, Inc., Exelixis, Inc., The Medicines Company, Human Genome Sciences Inc., United Therapeutics Corporation, Incyte Corporation, ViroPharma Incorporated.

Performance Peer Group

NA

COMPENSATION COMMITTEE MEMBERS

Director	Membership	Age	Gender	Tenure	Independence
Oliver S. Fetzner	Chairman	47	Male	7	Outside
Paul A. Friedman	Member	70	Male	2	Outside
Rolf A. Classon	Member	67	Male	8	Outside

This report is for informational purposes only, and should not be considered a solicitation to buy or sell any security. Thomson Reuters Business Classification (TRBC) is a global industry classification system that is owned and operated by Thomson Reuters and has been licensed for use by GMI Ratings.

COPYRIGHT 2012 |GMI Ratings | ALL RIGHTS RESERVED